Roche scores a no­table PhI­II suc­cess with Tecen­triq com­bo in blad­der can­cer, but is this an­oth­er case of too lit­tle too late?

Two years af­ter Roche’s PD-L1 drug Tecen­triq failed a key test for front­line blad­der can­cer as a monother­a­py, in­ves­ti­ga­tors are back with Phase III ev­i­dence that their check­point tied to chemo can do some good for pa­tients.

Their IMvig­or130 study came through on the co-pri­ma­ry end­point for pro­gres­sion-free sur­vival, but they’ll have to wait for the da­ta to ma­ture more be­fore they make the call on over­all sur­vival.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.